Press & media kit

Built to be cited.

Caveat is the independent, evidence-based claim-checker for the longevity industry. Everything here is free to quote. If you are writing about a supplement, peptide, device or protocol, the verdicts below are sourced, graded and ready to reference.

What we are

Independent. Sourced. Anti-hype.

Caveat checks what influencers and brands claim about supplements, peptides, wearables and biomarker tests against what the evidence actually shows, sources cited, evidence graded GRADE-style, conflicts of interest flagged, and the limits named out loud. Independent. No industry money.

The promise

Every check traces a claim to its primary source, quotes it exactly, grades the evidence GRADE-style (A high to D very low), follows the funding, and names the limits out loud.

The independence

No industry money, no affiliate revenue behind a verdict. When the evidence is thin we say “unproven,” not “disproven.” When a claim holds up, we say so.

By the numbers

The catalogue at a glance.

103

claim-checks, each independently sourced

636

citations, every one verified

14

categories, supplements to diagnostics

0

dollars of industry money

Verdicts across the catalogue

  • Mixed37
  • Unproven22
  • Misleading21
  • Unsupported15
  • Supported8

Full breakdown by verdict, evidence grade and category in the State of Longevity Claims report.

How to cite us

Quote freely. Link back.

Every check page has a Cite this check box with a copy-paste verdict card and ready citations. The general format:

"<claim>" Caveat verdict: <Verdict> (evidence grade <A to D>). caveat-ai.com/checks/<slug>

Prefer a feed? Every verdict ships in the RSS feed, and there is a machine-readable map for AI answer engines at /llms.txt.

The author

A real name on every word.

Brand & assets

Using the name and mark.

Name

The product is Caveat (wordmark caveat.ai), online at caveat-ai.com. Tagline: “Every claim has a caveat.” Please link the name to the site on first mention.

Covering a longevity claim? Use ours.